CTLs are targeted to kill β cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope by Skowera, Ania et al.
Research article
3390	 The	Journal	of	Clinical	Investigation	 	 	 http://www.jci.org	 	 	 Volume 118	 	 	 Number 10	 	 	 October 2008
CTLs are targeted to kill β cells in patients 
with type 1 diabetes through recognition of  
a glucose-regulated preproinsulin epitope
Ania Skowera,1,2 Richard J. Ellis,1 Ruben Varela-Calviño,3 Sefina Arif,1 Guo Cai Huang,4  
Cassie Van-Krinks,1 Anna Zaremba,1 Chloe Rackham,1 Jennifer S. Allen,1  
Timothy I.M. Tree,1 Min Zhao,4 Colin M. Dayan,5 Andrew K. Sewell,6 Wendy Unger,7  
Jan W. Drijfhout,7 Ferry Ossendorp,7 Bart O. Roep,7 and Mark Peakman1,2
1Department of Immunobiology, King’s College London, London, United Kingdom. 2National Institute for Health Research (NIHR),  
Biomedical Research Centre, Guy’s and St. Thomas’ NHS Foundation Trust and King’s College London, London, United Kingdom.  
3Department of Biochemistry, Faculty of Pharmacy, University of Santiago de Compostela, Spain. 4Diabetes Research Group, School of Medicine,  
King’s College London, London, United Kingdom. 5Henry Wellcome Laboratories for Integrative Neuroscience and Endocrinology,  
University of Bristol, Bristol, United Kingdom. 6Department of Medical Biochemistry and Immunology, Cardiff University School of Medicine, Heath Park, 
Cardiff, United Kingdom. 7Department of Immunohaematology and Blood Transfusion, Leiden University Medical Centre, Leiden, The Netherlands.
The	final	pathway	of	β	cell	destruction	leading	to	insulin	deficiency,	hyperglycemia,	and	clinical	type	1	dia-
betes	is	unknown.	Here	we	show	that	circulating	CTLs	can	kill	β	cells	via	recognition	of	a	glucose-regulated	
epitope.	First,	we	identified	2	naturally	processed	epitopes	from	the	human	preproinsulin	signal	peptide	by	
elution	from	HLA-A2	(specifically,	the	protein	encoded	by	the	A*0201	allele)	molecules.	Processing	of	these	
was	unconventional,	requiring	neither	the	proteasome	nor	transporter	associated	with	processing	(TAP).	
However,	both	epitopes	were	major	targets	for	circulating	effector	CD8+	T	cells	from	HLA-A2+	patients	with	
type	1	diabetes.	Moreover,	cloned	preproinsulin	signal	peptide–specific	CD8+	T	cells	killed	human	β	cells	in	
vitro.	Critically,	at	high	glucose	concentration,	β	cell	presentation	of	preproinsulin	signal	epitope	increased,	
as	did	CTL	killing.	This	study	provides	direct	evidence	that	autoreactive	CTLs	are	present	in	the	circulation	of	
patients	with	type	1	diabetes	and	that	they	can	kill	human	β	cells.	These	results	also	identify	a	mechanism	of	
self-antigen	presentation	that	is	under	pathophysiological	regulation	and	could	expose	insulin-producing	β	
cells	to	increasing	cytotoxicity	at	the	later	stages	of	the	development	of	clinical	diabetes.	Our	findings	suggest	
that	autoreactive	CTLs	are	important	targets	for	immune-based	interventions	in	type	1	diabetes	and	argue	for	
early,	aggressive	insulin	therapy	to	preserve	remaining	β	cells.
Introduction
The final molecular and cellular pathways leading to β cell destruc-
tion in the human autoimmune disease type 1 diabetes are not 
known. Any resolution of this question must address the mecha-
nism through which insulin-producing β cells, but not adjacent, 
non-β endocrine cells (α, δ, and PP cells secreting the hormones 
glucagon, somatostatin, and pancreatic polypeptide), are singled 
out for killing. Two distinct hypotheses have emerged. The first 
proposes that β cells die as a result of their selective susceptibil-
ity to inflammatory mediators, such as cytokines, nitric oxide, 
and oxygen free radicals (1), released by islet-infiltrating immune 
cells. The second states that CD8+ CTLs, recognizing β cell–spe-
cific peptides presented by HLA class I molecules, have the pivotal 
role in selective β cell death (2). In support of a CTL mechanism, 
postmortem studies of patients performed close to diabetes onset 
show numerical dominance of CD8+ T cells in the characteristic 
islet mononuclear cell infiltrate (3–5). Genetic susceptibility to 
disease is linked to inheritance of selected class I HLA molecules, 
including HLA-A2 (A*0201) (6). In animal models, efficient adop-
tive transfer of disease typically requires CD8+ T cells (2), and dia-
betes is prevented by genetic modifications that abrogate MHC 
class I molecule expression (7). Moreover, transgenic introduction 
of HLA-A2*0201 into diabetes-prone NOD mice markedly acceler-
ates disease development (8).
Despite these pieces of circumstantial evidence, however, to 
date there are no published reports demonstrating CTL killing of 
human β cells. This gap in our knowledge is a result of many con-
straints on such studies. Most importantly, islet-infiltrating T cells 
from patients with diabetes are very rarely available for expansion 
and cloning to examine their CTL potential, while the search for 
such cells trafficking in the peripheral blood requires prior knowl-
edge of the autoantigens targeted and the epitopes and HLA-pre-
senting molecules involved. To address these requirements, we 
chose to create surrogate β cells expressing a single autoantigen 
and HLA class I molecule and investigate their naturally dis-
played peptide repertoire. This uncovered the signal peptide (SP) 
as a source of preproinsulin (PPI) epitopes that constitute major 
targets of CD8+ T cell responses in HLA-A2+ patients with type 1 
diabetes. We show that expanded clones of PPI SP–specific CD8+ 
T cells kill human HLA-A2–expressing β cells in vitro, especially 
when β cells are exposed to high glucose concentrations. It has 
long been speculated that β cells, stressed by the need to control 
blood glucose levels as diabetes develops, could become enhanced 
targets for the immune system. Our study provides evidence of a 
mechanism through which this can occur.
Nonstandard	abbreviations	used: MS, mass spectrometry; PPI, preproinsulin; SP, 
signal peptide; TAP, transporter associated with processing; TFA, trifluoroacetic acid.
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Results
Identification of PPI epitopes. We elected to study PPI as a target 
autoantigen in type 1 diabetes because of its β cell specificity; the 
fact that we and others have shown its importance as a target of 
CD4+ T cell responses in clinical diabetes in humans (9–11); and 
in view of its prominent involvement in murine diabetes mod-
els (12). Since access to sufficient numbers of human β cells to 
study the peptide repertoire is not feasible, we elected to gener-
ate a “surrogate β cell.” The HLA-negative chronic myelogenous 
leukemia cell line K562 was selected as an appropriate carrier 
cell and transfected with PPI and HLA-A*0201 genes to derive 
a surrogate human β cell (termed K562-PPI-A2) that secretes 
proinsulin and expresses HLA-A2 (Figure 1, A and B). Peptides 
were acid eluted from the surface HLA-A2 molecules, and using 
a subtractive approach, we identified peptide species unique to 
K562-PPI-A2 cells and not present in either the control K562-PPI 
or K562-A2 single gene–transfected cell lines (Figure 1, C–F). 
Two prominent peptides were identified by mass spectrometry 
(MS) and sequenced by MS/MS and collision-induced dissocia-
tion, matching to PPI17–24 (WGPDPAAA) and PPI15–24 (ALWGP-
DPAAA) (Figure 2, A and B).
Disease relevance of SP epitopes of PPI. The finding that the major 
peptide species presented from PPI-expressing cells are located in 
the SP (Figure 2C) was unexpected and led us to examine their dis-
ease relevance. Circulating IFN-γ–producing CD8+ T cells specific 
for these epitopes were detected by ELISPOT assay (9) in approxi-
mately 50% of patients with new-onset type 1 diabetes who possess 
the HLA-A*0201 genotype (Figure 3, Table 1, and Supplemental 
Table 1; supplemental material available online with this article; 
doi:10.1172/JCI35449DS1). CD8 responsiveness was confirmed 
by disappearance of ELISPOT reactivity after immunomagnetic 
depletion of CD8+ T cells, as described previously (9). In contrast, 
this reactivity was rare in HLA-A2–negative type 1 diabetes patients 
(2 of 12 patients [17%] positive to either peptide; P < 0.05 versus 
HLA-A2+ patients). Responses to PPI15–24, either or both epitopes 
were significantly more frequent in HLA-A2+ patients than in 
Figure 1
Generation of surrogate β cell lines and examination of their naturally processed and presented peptide repertoire. The chronic myelogenous 
leukemia cell line K562 was variously transfected with the genes for PPI and HLA-A*0201. (A) This yielded cell lines (denoted K562-PPI and 
K562-PPI-A2) that secrete proinsulin (gray bars) and immunoreactive insulin species (black bars) into cell culture supernatants. No proinsulin or 
immunoreactive insulin is secreted by single-transfected K562-A2 cells. Bars represent mean levels present in cell supernatants and error bars 
the SEM. (B) Surface HLA-A2 expression was examined by flow cytometry using the allele-specific mAb BB7.2, showing comparable HLA-A2 
levels on the K562-A2 (solid line) and K562-PPI-A2 (dashed line) cells compared with absence of staining on K562-PPI cells (dotted line). Iso-
type control staining was similar to K562-PPI staining on all cell lines, and similar results were obtained with the pan–HLA-A,B,C–staining mAb 
W6/32. K562-PPI-A2 and K562-A2 cell lines were grown in large cultures and the natural peptide repertoire extracted and resolved by RP-HPLC, 
and fractions were compared by MS to identify masses unique to PPI-expressing cells. (C and D) MS analysis of HPLC fractions 55 and 65, 
respectively, from K562-PPI-A2 cells. Arrows indicate masses unique to these cells (784.37 and 968.48 m/z, respectively) that are not found in 
the equivalent (or adjacent) fractions from K562-A2 cells (E and F) or K562-PPI cells (data not shown).
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HLA-matched nondiabetic control subjects (Figure 3). The pres-
ence of circulating effector CD8+ T cells recognizing these epitopes 
is therefore specific for disease and HLA-A2. Indeed, we were able 
to conclude that SP epitopes constitute major targets of the CD8+ 
T cell response against PPI in type 1 diabetes, since the frequencies 
of responses we detected to these epitopes were higher than those 
to a range of other putative HLA-A2–restricted epitopes from 
insulin/proinsulin that are currently being investigated in paral-
lel studies in our laboratory (insulin B10–18 [refs. 13, 14], 27% of 
patients; B18–27 [ref. 15], 27%; C22–30 [ref. 13], 14%; C27–35 [ref. 
13], 23%; proinsulin C31–A5 [ref. 13], 9%; and insulin A1–10 [ref. 
13], 18%) (data not shown).
Phenotype and target cell killing of PPI15–24–reactive CD8+ T cells. To 
examine the functional properties of PPI SP–reactive CD8+ T cells, 
we established short-term CD8+ T cell lines from HLA-A2+ patients 
with type 1 diabetes who showed appropriate ELISPOT reactivity, 
focusing on the PPI15–24 epitope because of its relative immuno-
dominance (Figure 3). From these lines, cells staining with PPI15–24– 
loaded HLA-A2 tetramers (PPI15–24–Tmr) were sorted by flow cytom-
etry and expanded, yielding 5 PPI15–24–Tmr+CD8+ T cell clones from 
a single patient (Figure 4, A and B). Three of these clones (1E6, 3F2, 
and 1C8) have been characterized in detail at a functional level 
(see below), and each is known to express TCR β variable chain 
gene TRBV12-4 and 2 productively rearranged TCR α chain genes, 
TRAV12-3 and TRAV13-2. Interestingly, a clone with the same TRBV 
and TRAV expression, and TRBV CDR3 sequence identical to 1E6, 
was isolated from fresh blood obtained from the same patient 1.5 
years after the first sample, in a “honeymoon” phase of the disease, 
during which insulin treatment was temporarily not required. Thus, 
while it is difficult to be certain whether the clones we originally 
obtained are independent or duplicate cloning events, our data show 
that their ancestral clone is long-lived and likely to be dominant in 
this patient. Future studies will be required to address whether simi-
lar clones are found in other patients and what additional specifici-
ties are responsible for their ELISPOT reactivity.
Clones showed HLA-A2–restricted responses to PPI15–24, either 
when PPI15–24 peptide was presented after pulsing of HLA-A2– 
autologous antigen-presenting cells (Figure 4, C and D) or 
when it was presented naturally by K562-PPI-A2 cells (Figure 
4E). PPI15–24–specific T cell clones did not recognize PPI17–24. In 
contrast, using an identical approach, we were unable to isolate 
PPI15–24–specific CD8+ T cell clones from healthy HLA-A2+ non-
diabetic donors (n = 3).
After antigenic stimulation, PPI15–24–specific CD8+ T cell clones 
predominantly produced TNF-α (Figure 4, C and E), in addition 
to IFN-γ, and expressed the chemokine receptors CXCR3 and 
CCR4, both of which have been shown to be important in CD8+ 
T cell participation in autoimmune models of type 1 diabetes (16, 
17) (Supplemental Figure 1). Clones also expressed surface mark-
ers characteristic of an effector CD8+ T cell phenotype (Supple-
Figure 2
Mass spectrometry analysis of unique eluted masses. MS/MS analysis of the unique masses using collision-induced dissociation (CID) reveals 
their identity. Plots show fragmentation patterns of the 784.37 m/z (A) and 968.48 m/z (B) species under CID in atmospheric gas, revealing a 
series of ions (y, b, and a) and fragments (PD/DP, GPD, and GPDPA) that identify the parent ions as WGPDPAAA (PPI17–24, predicted monoiso-
topic mass, 784.3624 Da) and ALWGPDPAAA (PPI15–24, predicted monoisotopic mass, 968.4836 Da), respectively. These sequences map to the 
SP of PPI. These results, from the starting cellular material onward, were replicated in a further 2 independent experiments. (C) Representation 
of the SP region of PPI and beginning of the B chain of insulin. Both eluted peptides terminate at residue 24, the signal peptidase cleavage site. 
The transmembrane region of SP is shown, as predicted from SignalP-HMM (51) and Kyte-Doolittle (52) hydrophobicity plots, and indicates that 
residue 17 is immediately after the transmembrane segment, while the NH2 terminus of PPI15–24 commences in the intramembrane segment.
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mental Figure 1). The killing potential of PPI15–24–specific CD8+ 
T cell clones was revealed by expression of cytolysins including 
granzyme B, perforin, and TNF-related apoptosis-inducing ligand 
(TRAIL; Supplemental Figure 1).
To examine antigen-specific CTL activity of PPI15–24–reactive 
CD8+ T cells, we first used K562-PPI-A2 cells as targets in a conven-
tional cytotoxicity assay. Killing was highly efficient and restrict-
ed to K562 cells expressing both PPI and HLA-A2 (Figure 5A). 
Figure 3
Circulating effector CD8+ T cells that recognize PPI SP epitopes are 
present in patients with type 1 diabetes. IFN-γ ELISPOT PBMC reactiv-
ity to PPI15–24, either PPI17–24 or PPI15–24, or both peptides was signifi-
cantly more frequent in patients with type 1 diabetes and HLA-A*0201 
(black bars) than in HLA-matched nondiabetic control subjects (white 
bars). Responses to PPI17–24 were not significantly different in this 
series (P = 0.08), but see Supplemental Table 1 showing a similar 
analysis of an extended, independent series of cases in which the 
prevalence of responses to PPI17–24 is significantly higher in patients 
with type 1 diabetes than in control subjects (P = 0.004). In contrast, 
the prevalence of responses to the mixture of viral peptides was similar 
in the 2 groups (see also Supplemental Table 1).
Table 1
IFN-γ ELISPOT response to PPI peptides in HLA-A2+ type 1 diabetes patients and HLA-A2+ nondiabetic control subjects
	Clinical	details	 	 	 	Raw	counts	(spots/million	PBMCs)	 	 	 	 Stimulation	index
Case	 Age		 Sex	 Bgd	 A2140–149	 CSP334–342	 PDC159–167	 CEF	 PPI17–24	 PPI15–24	 A2140–149	 CSP334–342	 PDC159–167	 CEF	 PPI17–24	 PPI15–24	
	 (yr)
T1D
1 30 M 10 15 13 15 63 19 29 1.5 1.3 1.5 6.3 1.9 2.9
2 21 M 5 1 0 1 199 28 19 0.2 0.0 0.2 39.8	 5.6	 3.8
3 38 M 3 5 3 5 31 5 5 1.7 1.0 1.7 10.3 1.7 1.7
4 31 F 1 1 0 0 10 3 0 1.0 0.0 0.0 10.0	 3.0 0.0
5 20 M 4 2 4 6 19 6 5 0.5 1.0 1.5 4.8 1.5 1.3
6 21 F 5 5 5 5 105 5 9 1.0 1.0 1.0 21.0 1.0 1.8
7 23 M 10 5 3 3 237 12 56 0.5 0.3 0.3 23.7 1.2 5.6
8 32 F 3 3 5 3 216 12 9 1.0 1.7 1.0 72.0	 4.0	 3.0
9 24 F 2 3 8 4 7 9 6 1.5 4.0 2.0 3.5	 4.5	 3.0
10 21 M 2 1 2 1 31 11 5 0.5 1.0 0.5 15.5	 5.5	 2.5
11 18 F 4 2 0 1 17 4 5 0.5 0.0 0.3 4.3 1.0 1.3
12 35 F 11 14 13 11 221 35 36 1.3 1.2 1.0 20.1	 3.2	 3.3
13 18 F 3 5 1 1 15 2 2 1.7 0.3 0.3 5.0 0.7 0.7
14 35 M 11 10 11 10 279 11 26 0.9 1.0 0.9	 25.4 1.0 2.4
15 30 M 9 12 6 5 51 8 8 1.3 0.7 0.6 5.7 0.9 0.9
NCs
C1 32 F 11 5 13 4 192 2 20 0.5 1.2 0.4 17.5 0.2 1.8
C2 23 M 7 1 0 1 144 3 1 0.1 0.0 0.1 20.6 0.4 0.1
C3 28 F 1 0 1 0 30 1 0 0.0 1.0 0.0 30.0 1.0 0.0
C4 33 F 15 13 10 10 44 18 10 0.9 0.7 0.7 2.9 1.2 0.7
C5 36 F 12 6 11 21 115 13 8 0.5 0.9 1.8 9.6 1.1 0.7
C6 33 F 13 23 15 9 241 15 6 1.8 1.2 0.7 18.5 1.2 0.5
C7 29 M 12 5 17 10 173 11 7 0.4 1.4 0.8 14.4 0.9 0.6
C8 23 F 4 4 2 1 91 3 7 1.0 0.5 0.3 22.8 0.8 1.8
C9 34 M 8 15 24 27 38 24 13 1.9 3.0	 3.4	 4.8	 3.0 1.6
C10 27 F 8 5 13 4 183 3 20 0.6 1.6 0.5 22.9 0.4 2.5
C11 29 F 6 3 1 2 231 6 1 0.5 0.2 0.3 38.5 1.0 0.2
C12 34 M 2 3 3 3 282 3 0 1.5 1.5 1.5 141.0 1.5 0.0
C13 31 M 16 7 12 3 40 6 6 0.4 0.8 0.2 2.5 0.4 0.4
C14 20 M 2 0 1 1 29 0 0 0.0 0.5 0.5 14.5 0.0 0.0
C15 29 M 12 6 13 2 96 4 1 0.5 1.1 0.2 8.0 0.3 0.1
Bgd, background (DMSO) spots; control peptides A2140–149 from HLA-A2; CSP334–342 from Plasmodium falciparum circumsporozoite; and PDC159–167 from 
the E2 pyruvate dehydrogenase complex. Bold indicates positive response (stimulation index, ≥2.0). CEF, mix of viral peptides as positive control; NCs, 
nondiabetic control subjects; T1D, type 1 diabetes patients.
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These results indicate that circulating autoreactive CD8+ T cells 
in patients with type 1 diabetes recognize β cell–specific targets 
and have cytotoxic capability.
PPI-specific CD8+ T cells kill human β cells. We next labeled monodis-
persed preparations of human islet cells that were HLA-A2+, isolated 
from pancreatic islets obtained from organ donors, to examine the 
key question of β cell killing. PPI15–24–specific CD8+ T cells killed 
human islet cells in an HLA-A2–restricted manner (Figure 5B and 
Supplemental Figure 2). Killing of human islet cells appeared to 
require cell-cell contact mechanisms, such as cytolysin release direct-
ly onto target cell membranes, since the supernatants from CTLs 
activated with cognate peptide had no cytotoxic effects on human 
islet cells or K562-PPI-A2 (data not shown). Moreover, the killing of 
human islet cells by PPI15–24–specific CD8+ T cell clones was selec-
tive for the β cell. Semiquantitative RT-PCR analysis of mRNA for 
insulin (specific for β cells) and glucagon (specific for α cells, which 
are not destroyed in type 1 diabetes) in human islet cells after expo-
sure to PPI15–24–specific CTLs revealed a marked reduction in insu-
lin expression (Figure 5, C and D, lane 2) when compared with islet 
cells cultured alone (lane 1) or with an irrelevant (HLA-A2–restricted 
Figure 4
Generation of CD8+ T cell clones specific for PPI SP epitope PPI15–24. (A) Five clones isolated from a patient with type 1 diabetes stained with 
anti-CD8 and HLA-A2 tetramers loaded with PPI15–24. Tetramer-stained cells were detected in the upper-right quadrant. A CD8+ T cell clone 
obtained in the same expansion that was negative for PPI15–24–Tmr (3C9) and a clone (2D9) raised against the CMV pp65 epitope NLVPMVATV 
are shown. (B) Staining of the same clones with HLA-A2 tetramers loaded with the CMV pp65 epitope NLVPMVATV. (C) PPI15–24–specific T 
cell clones produce TNF-α in a dose-dependent fashion, shown here as the percentage of 1E6 clone cells staining for intracellular cytokine in 
response to HLA-A2+ PBMCs pulsed with varying concentrations of PPI15–24. (D) 1E6 clone cells proliferate in response to PPI15–24 peptide-pulsed 
monocyte-derived DCs, as measured by [3H]thymidine incorporation. No response was observed using antigen-presenting cells lacking HLA-A2 
(data not shown). (E) 1E6 clone cells also recognize the PPI15–24 epitope when naturally processed by K562-PPI-A2 cells, since no TNF-α was 
produced after coculture with K562-A2 cells, but in the presence of PPI15–24 peptide-pulsed K562-A2 (1 μg/ml) or K562-PPI-A2 cells, copious 
amounts of cytokine were produced. Isotype control staining was similar to control-activated clone cells. Proliferation assays were performed 
in triplicate; bars represent means, error bars are SEMs. Values inside flow cytometry quadrants indicate percentage of positive cells. Data are 
representative of more than 5 individual experiments.
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CMV peptide–specific) CTL clone (lane 3). Under similar conditions, 
glucagon expression remained unchanged (Figure 5, C and D), indi-
cating that β cells were being targeted selectively for killing in these 
assays. Importantly, these studies confirm that the PPI SP epitope 
PPI15–24 is naturally processed and presented by human β cells, as 
well as their engineered surrogates.
Processing and presentation of PPI SP epitopes. HLA class I molecule 
presentation of SPs is unusual, being most typically observed in 
the absence of functioning transporter associated with process-
ing (TAP) (18). However, this seemed an unlikely explanation 
for our observation, since K562 cells are TAP replete. Moreover, 
processing and presentation of PPI15–24 by K562-PPI-A2 cells is 
not affected by cotransfection with the gene encoding the vari-
cellovirus-derived TAP inhibitor protein UL49.5 (19) (Figure 6A). 
In addition, digestion of a PPI1–30 peptide by both constitutive 
and immunoproteasomes did not identify any products match-
ing to NH2-terminal extensions of peptides with COOH terminus 
at residue 24 and of appropriate length. Table 2 shows 
average masses for putative NH2-terminally extended 
peptide species with a COOH terminus at residue 24 
and length of 8-mer or greater. None of these species 
was detected after proteasome digestion, although sev-
eral other fragments of PPI1–30 were found (Figure 6B). 
Since conventional generation of HLA class I epitopes 
requires that the correct COOH terminus is generated 
by the proteasome (since COOH-terminal trimming 
does not occur), this makes it unlikely that PPI15–24 
and PPI17–24 are derived by proteasomal cleavage. The 
lack of requirement for TAP transport or proteasomal 
cleavage in the generation and loading of PPI17–24 and 
PPI15–24 suggests that they are generated within the ER, 
rather than via retrograde translocation of PPI frag-
ments into the cytoplasm for conventional processing. 
Indeed, we demonstrate that intact PPI17–24 is gener-
ated by soluble ER proteases and that PPI15–24 is likely 
to require a combination of these and intramembrane 
proteolysis (see Supplemental Results). Overall, these 
data indicate an unconventional processing route for 
PPI17–24 and PPI15–24, which includes signal peptidase 
activity, soluble ER proteases, and intramembrane-
cleaving proteases (I-CLiPs), the nature and specificity 
of which remain to be established.
Effects of glucose concentration on β cell killing. The uncon-
ventional nature of processing of the PPI SP epitopes is 
reminiscent of that reported for Jaw1, which is inserted 
into ER membranes and from which C-terminal (lume-
nal) peptides undergo class I processing and presenta-
tion via TAP- and proteasome-independent mecha-
nisms (20). It has been speculated that such processing 
is explained by the protrusion of domains into the ER 
lumen, facilitating direct loading into nascent class I 
molecules (21). This led us to hypothesize that the effi-
ciency of HLA class I presentation of PPI SP epitopes 
would be directly influenced by the availability of sub-
strate, namely newly synthesized PPI. To explore this, 
human islet cells were cultured at 5.6, 11, and 20 mM 
glucose for 16 hours before exposure to PPI15–24–spe-
cific T cells and measurement of TNF-α production 
by the T cell clone. As glucose concentration increased, 
more insulin mRNA was expressed by β cells (Figure 7, 
A and B), and in concert TNF-α production by PPI15–24–specific T 
cells increased significantly (P < 0.01) and linearly (test for linear 
trend, P < 0.005; Figure 7C). In contrast, TNF-α production was 
not influenced by glucose concentration when islet cells were pre-
pulsed with PPI15–24 peptide (P = NS; Figure 7D).
This finding prompted us to examine whether increased activa-
tion of PPI15–24–specific CTLs by islet cells exposed to high glucose 
concentration could result in enhanced β cell killing. As shown in 
Figure 8A, stepwise increases in ambient glucose concentration 
resulted in significant (P < 0.005) and linear (P < 0.005) increases 
in killing by the CTL clone 1E6 and other clones (Supplemental 
Figure 2). β Cell specificity was confirmed by a stepwise decline in 
levels of insulin mRNA as CTL killing increased (Figure 8, B and 
C). Moreover, the increased killing was not a result of increased 
fragility of β cells, since killing of PPI15–24 peptide–pulsed islet cells 
was not significantly altered by high ambient glucose (P = NS; Fig-
ure 8D) and was not β cell specific (Figure 8, E and F). Moreover, 
Figure 5
CD8+ T cell clones specific for PPI SP epitope PPI15–24 are cytotoxic and kill human 
β cells. (A) Percent specific lysis of K562-PPI-A2 cells by 1E6 PPI15–24–specific T 
cell clone (open squares) but not K562-A2 (triangles) or K562-PPI cells (data not 
shown). Control CTL 2D9 recognizing A2-presented CMV pp65495–503 does not kill 
K562-PPI-A2 cells (open circles). Both clones kill K562-A2 and K562-PPI-A2 cells 
prepulsed with respective cognate peptide (lysis >90% at 25:1 effector/target ratio; 
data not shown). (B) Lysis of human HLA-A2+ (open squares) islet cells by 1E6. 
A2-negative islet cells (triangles) were not killed, and there was no killing by 2D9 
(open circles). A2+ (but not HLA-A2–) islet cells prepulsed with PPI15–24 were killed 
(lysis >90% at 25:1; data not shown). Representative of 5 assays for K562 and 
3 for human islets (including 2 different donors), performed in triplicate (data are 
presented as mean, with error bars representing SEMs). (C) Representative (from 
3 independent experiments) agarose gel resolution of semiquantitative RT-PCR 
amplification from human islet cell cytotoxicity assays using insulin- and gluca-
gon-specific primers. (D) PCR product density relative to β-actin (IOD, integrated 
optical density). A greater than 4-fold reduction in insulin mRNA when islet cells 
were cultured with 1E6 PPI15–24–specific CTLs is seen (lane 2; IOD, 50.0 × 103), 
compared with no added clone (lane 1; IOD, 202.0 × 103). No reduction in insulin 
expression is seen in the presence of 2D9 (lane 3). Glucagon expression is similar 
under all conditions, indicating that killing of human islet cells by 1E6 PPI15–24–spe-
cific CTLs is β cell specific.
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over a 16-hour period in the presence of high glucose (20 mM), 
islet killing peaked when insulin mRNA transcripts were most 
abundant, rather than when insulin secretion was at its highest 
(Figure 9). Taken together, these data show that when β cells are 
induced to increase PPI synthesis, there is a concomitant increase 
in PPI SP epitope presentation. In the presence of specific CTLs, 
such β cells are subjected to a greater β cell killing efficiency. Pro-
longed exposure to high glucose concentrations was required to 
see the effect, since killing was not enhanced when islets were 
exposed to 20 mM glucose for 30 minutes before the cytotoxicity 
assay (data not shown).
Cross-presentation of PPI SP epitopes. Having established the impor-
tance of the PPI15–24 epitope in β cell targeting, we questioned how 
specific effector CD8+ T cells could be primed to recognize this 
epitope during the pathogenesis of type 1 diabetes. CTL prim-
ing requires cross-presentation, a process in which professional 
antigen-presenting cells such as DCs take up, process, and pres-
ent antigens as peptide–HLA class I molecule complexes to naive 
CD8+ T cells. This process is a necessary component of immunity, 
for example, against viruses that do not infect antigen-presenting 
cells, but its involvement in autoimmune disease is relatively unex-
plored. Moreover, in this particular context, it is clear that intact 
PPI, from which PPI15–24 is derived, is ER membrane inserted and 
not directly available for extracellular uptake as a soluble protein. 
Tang and colleagues have shown that in the NOD mouse model 
of autoimmune diabetes, whole β cells are ingested by DCs and 
transported to the pancreatic lymph node (22). We therefore exam-
ined whether DCs cultured with soluble PPI or with K562-PPI cells 
could cross-present PPI15–24 to specific T cell clones. Our results 
show that DCs are efficient at cross-presentation of PPI15–24 from 
soluble PPI and also from intact PPI-expressing cells (Figure 10).
Discussion
The novelty of this study is 4-fold. First, it provides evidence that 
human autoreactive CD8+ T cells can be responsible for the selec-
tive β cell destruction that is the hallmark of clinical type 1 diabe-
Figure 6
Generation of SP epitopes of PPI is independent of TAP. (A) To examine TAP dependency of PPI15–24 presentation by K562 cells, the CTL clone 
(1E6) recognizing PPI15–24 restricted by HLA-A2 was used in cytotoxicity assays in the presence of the varicellovirus-derived TAP inhibitor UL49.5 
(19). As a control, we used the HA-2 CTL clone 5H17 (53), specific for an endogenously expressed, TAP-dependent minor histocompatibility 
antigenic epitope (sequence YIGEVLVSV derived from a diallelic gene encoding a novel human class I myosin protein) presented by HLA-A2 (54). 
Target cells for clone 1E6 were K562-PPI-A2 cells or K562-PPI-A2 cells additionally transfected to express UL49.5. Target cells for clone 5H17 
were K562-A2 cells or K562-A2 cells additionally transfected to express UL49.5. Data are expressed as percent killing (see Methods for calculation 
of specific cytotoxicity using DELFIA assay); bars represent means and error bars, SEMs. In the presence of the 1E6 PPI15–24–specific CTLs, killing 
of K562-PPI-A2 cells cotransfected with UL49.5 (black bars) was comparable to that of untransfected K562-PPI-A2 cells (white bars), indicating 
that TAP inhibition by UL49.5 does not reduce PPI15–24 presentation. In contrast, killing of target cells by the HA-2–specific CTL 5H17 that recog-
nizes a TAP-dependent epitope is markedly inhibited in the presence of UL49.5 (black bars). (B) To examine proteasome dependency of PPI15–24 
generation, MS analyses of immuno- and constitutive proteasome digests of PPI1–30 were performed. Results are shown in Table 2. In the same 
experiment, several other fragments of PPI1–30 were generated by proteasome digestion. Sequences marked with an asterisk were generated by 
the constitutive proteasome only. For reference, the 10-mer PPI15–24 peptide eluted from surrogate β cells is indicated by the black rectangle.
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tes. Second, it also reveals that a relatively unstudied portion of the 
SP of PPI is a major source of CTL targets. Third, these epitopes 
are generated by an unconventional processing pathway that is 
influenced by the ambient glucose concentration. Finally, β cells 
can therefore unwittingly be active players in their own demise, 
being targeted more efficiently as they are induced to secrete more 
insulin. These findings may have important disease implications. 
In prediabetic subjects in vivo, it is likely that individual β cells 
are required to increase insulin secretion, as the total β cell mass 
diminishes during the asymptomatic prodrome of the disease. 
Thus, the microenvironmental conditions prevailing in islets of 
Langerhans as clinical type 1 diabetes approaches, which include 
the well-documented β cell hyperexpression of HLA class I mole-
cules (3, 5, 23) coupled with increased secretion of insulin, provide 
optimal killing conditions for CTLs that may be present.
Although putative epitopes of insulin, proinsulin, and PPI have 
been identified through the use of predictive HLA class I binding 
algorithms (15, 24), immunization of HLA class I–transgenic mice 
(13), and proteasome digestion patterns (13–15, 25), none has been 
confirmed as being naturally processed by human β cells, and none 
has been identified as a target of CTLs. By focusing our epitope dis-
covery effort onto the naturally presented repertoire, we identified 
2 novel epitopes, both residing within the SP, and confirmed that 
at least one of these (PPI15–24) is naturally presented by human β 
cells. SP epitopes are unusual, and, to our knowledge, none of rel-
evance to human disease have been described to date. We provide 
strong evidence that the processing of PPI SP for presentation by 
HLA class I molecules does not follow the conventional route (i.e., 
via proteasome cleavage and TAP transport), requiring instead the 
activity of soluble and membrane-bound ER proteases. β Cell pro-
cessing and presentation of the CTL epitope PPI15–24 is enhanced by 
a prolonged increase in ambient glucose. We consider it most likely 
that this results from an increase in available PPI substrate entering 
the ER membrane. Enhanced presentation will occur as the quan-
tity of PPI mRNA increases and it undergoes augmented cotransla-
tion alongside HLA-A2 mRNA, also upregulated on infiltrated islets 
and in our islet cultures (3). Such a rise in β cell PPI mRNA content 
requires exposure to high ambient glucose concentrations for pro-
longed periods in vitro (26), the corollary of which in vivo is likely to 
be prolonged hyperglycemia experienced, for example, in advanced, 
uncontrolled clinical diabetes. An alternative but not mutually exclu-
sive explanation is that ER stress, known to be a consequence of high 
ambient glucose (27), could upregulate the requisite ER processing 
machinery for SP, leading to enhanced PPI15–24 presentation.
The debate as to the mechanism of β cell death in type 1 diabetes 
has simmered for several years but has important clinical implica-
tions, since greater understanding in this area has the potential to 
guide novel immune intervention strategies. At present, none of the 
therapeutic approaches under evaluation in type 1 diabetes at phase 
I, II, or III stages is specifically designed to target autoreactive CD8+ 
T cells (28). Our finding that circulating CTLs capable of killing 
β cells are present in a sizeable proportion of patients with type 1 
diabetes legitimizes the development of CD8+ T cell–specific strat-
egies to halt β cell destruction, although the challenge will be to 
develop approaches that leave antiviral responses relatively intact. 
An example might be targeting of the NKG2D/MICA axis. The CTL 
clones we isolated from type 1 diabetes patients were NKG2D+, and 
blockade of the equivalent pathway in the NOD mouse prevents 
islet destruction and development of diabetes (29).
A second approach that might at least slow progression of β cell 
destruction would be to minimize endogenous insulin production 
through early and aggressive introduction of insulin therapy. The 
repeated observation that many patients who are insulin depen-
dent at diagnosis then temporarily cease to require insulin injec-
tions in subsequent months (the so-called honeymoon period) is 
consistent with the hypothesis that the introduction of exogenous 
Table 2
MS analysis of immuno- and constitutive proteasome digests of PPI1–30 shows proteasome-independence of PI15–24 generation
	 	 	 	 	 	 	 	 	 	 Proteasome
	 PPI	peptides	searched	for:	 Mass	 1+	(m/z)	 2+	(m/z)	 3+	(m/z)	 4+	(m/z)	 Constitutive	 Immuno-
 WGPDPAAA 783.84 784.84 392.92 262.28 196.96 ND ND
 LWGPDPAAA 897.00 898.00 449.50 300.00 225.25 ND ND
 ALWGPDPAAA 968.08 969.08 485.04 323.69 243.02 ND ND
 LALWGPDPAAA 1,081.24 1,082.24 541.62 361.41 271.31 ND ND
 LLALWGPDPAAA 1,194.40 1,195.40 598.20 399.13 299.60 ND ND
 ALLALWGPDPAAA 1,265.48 1,266.48 633.74 422.83 317.37 ND ND
 LALLALWGPDPAAA 1,378.63 1,379.63 690.32 460.54 345.66 ND ND
 LLALLALWGPDPAAA 1,491.79 1,492.79 746.90 498.26 373.95 ND ND
 PLLALLALWGPDPAAA 1,588.91 1,589.91 795.46 530.64 398.23 ND ND
 LPLLALLALWGPDPAAA 1,702.07 1,703.07 852.04 568.36 426.52 ND ND
 LLPLLALLALWGPDPAAA 1,815.23 1,816.23 908.62 606.08 454.81 ND ND
 RLLPLLALLALWGPDPAAA 1,971.42 1,972.42 986.71 658.14 493.86 ND ND
 MRLLPLLALLALWGPDPAAA 2,102.62 2,103.62 1,052.31 701.87 526.66 ND ND
 WMRLLPLLALLALWGPDPAAA 2,288.83 2,289.83 1,145.42 763.94 573.21 ND ND
 LWMRLLPLLALLALWGPDPAAA 2,401.99 2,402.99 1,202.00 801.66 601.50 ND ND
 ALWMRLLPLLALLALWGPDPAAA 2,473.07 2,474.07 1,237.54 825.36 619.27 ND ND
 MALWMRLLPLLALLALWGPDPAAA 2,604.27 2,605.27 1,303.14 869.09 652.07 ND ND
MS analyses of immuno- and constitutive proteasome digests of PPI1–30 as average masses for putative NH2-terminally extended peptide species with a 
COOH terminus at residue 24 and length of 8-mer or greater. The table lists m/z values of possible ionization species (1+ to 4+) for each of the hypotheti-
cal peptide products in the search. None of these species was detected after proteasome digestion, indicating a very low probability that the proteasome is 
able to generate the PPI15–24 and PPI17–24 SP epitopes. ND, not detected.
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insulin therapy allows targeted β cells to reduce their synthetic 
activity and thus acquire a degree of protection from CTL attack. 
Indeed, previous studies, albeit on small numbers of subjects, have 
suggested that preservation of endogenous insulin reserve might 
benefit from administration of insulin in the prediabetic period 
(30) or exertion of tight metabolic control soon after diagnosis (31). 
Our study provides a rational basis for such an approach by iden-
tifying a possible mechanism through which it operates. Finally, 
the novel pathway through which PPI SP epitopes are generated 
implies the existence of I-CLiPs and ER proteases that are critical 
for CTL epitope display. Identification of the precise components 
involved in PPI SP processing could lead to the development of 
novel therapeutic agents that target these pathways.
Methods
Generation of surrogate β cells. PPI cDNA was inserted between the BamHI and 
EcoRI sites in the pcDNA6/ myc-His B vector (Invitrogen) for expression 
in mammalian cell lines under blasticidin selection. The human chronic 
myelogenous leukemia cell line K562 expressing HLA-A2 
(K562-A2) under Geneticin resistance was obtained (32) 
from C. Britten (Johannes Gutenberg-University of Mainz, 
Mainz, Germany) and cultured in RPMI-1640 medium 
supplemented with 10% heat-inactivated FBS and 1% pen-
icillin/streptomycin solution (all Invitrogen) at 37°C, 5% 
CO2. Geneticin (Invitrogen) concentration in the medium 
was maintained at 0.7 mg/ml. HLA-A2 was expressed by 
greater than 95% of cells. Transfection of the PPI gene was 
carried out using Effectene (QIAGEN), and K562-PPI-A2 
cells were maintained in the same manner as K562-A2 cells 
with the addition of 10 μg/ml blasticidin. After 2 weeks 
of culture under selection, proinsulin (DRG International 
Inc.) and immunoreactive insulin (Diagnostic Systems 
Laboratories Inc.) were detected in the supernatants by 
ELISA and RIA, respectively.
Analysis of HLA-A2 peptide repertoire. Peptides were extract-
ed from the surface of cultured cells by citric acid elution 
(33). Briefly, 4 × 109 cells were washed 3 times in PBS and 
resuspended in a total volume of 25 ml of pH 3.3 citrate-
phosphate buffer (0.131 M citric acid, 0.066 M Na2HPO4) 
for 1 minute at room temperature. Cells were then pel-
leted and the supernatant citric acid solution (containing 
previously cell-bound HLA class I peptides) harvested and 
filtered through a 0.2-μm syringe filter before resolution 
using 2 Sep-Pak C18 cartridges (Waters) connected in 
series and conditioned using 50 ml acetonitrile and then 
50 ml citrate buffer. Peptides were eluted with 3 ml 80% 
acetonitrile per cartridge and vacuum dried to 50 μl. This 
residue was resuspended by addition of a further 150 μl 
citrate buffer. Peptides were additionally purified by ultra-
filtration through a 3,000-molecular-weight-cutoff Cen-
tricon-3 ultrafiltration concentrator (Millipore) at 6,500 g 
for 6 hours at 18°C. The filtrate (approximately 100 μl) 
was stored at –80°C prior to fractionation by reverse phase-
HPLC (RP-HPLC) on a Symmetry C18 column (Waters) 
connected to a Waters 2690 Separations Module and 2487 
Detector using water/0.05% trifluoroacetic acid (TFA) and 
acetonitrile/0.05% TFA with collection of 120 fractions. 
Each fraction was vacuum dried (SpeedVac vacuum con-
centrator; Thermo Scientific) at room temperature, to 
approximately 5–10 μl, and stored at –80°C.
For matrix assisted laser desorption/ionization time-of-flight (MALDI-
TOF) MS analysis of peptides, 0.5 μl sample was mixed with 0.5 μl freshly 
prepared 2,5-dihydroxybenzoic acid matrix (MassPREP DHB matrix; 
Waters) or α-cyano-4-hydroxycinnamic acid matrix (CHCA; Bruker Dalton-
ics) prepared at 10 mg/ml in 1:1 (v/v) acetonitrile, 0.1% TFA. For internal cal-
ibration, a further 1 μl MS calibrant mixture was added, containing 2.5 fmol 
leu-enkephalin (556.2771 m/z) and 5 fmol substance P (1347.73543 m/z). 
MS was performed using a Bruker Daltonics MALDI-TOF mass spectrom-
eter. Samples from K562-PPI-A2, K562-A2, and K562-PPI cells were ionized 
using laser intensities in the range of approximately 5,000 V and approxi-
mately 30,000 spectra acquired and compared to identify unique masses 
in the K562-PPI-A2 extract as described previously (9, 34). Spectra were 
aligned with internal calibrants for maximum accuracy using linear cali-
bration to enable matching of putative unique masses to linear sequences 
of PPI. Putative unique sequences, i.e., those found in K562-PPI-A2 but 
not control K562-A2 or K562-PPI fractions, could then be identified either 
manually or using computer algorithms. Unique masses were then charac-
terized by MS/MS using a Voyager ABI 4700 (Applied Biosystems) to derive 
Figure 7
High ambient glucose increases β cell PPI synthesis and activation of PPI SP epitope 
PPI15–24–specific CTLs and the efficiency of human β cell killing. (A) Agarose gel show-
ing resolution of products of semiquantitative RT-PCR amplification using insulin- and 
glucagon-specific primers from total RNA extracted from human islet cells cultured 
for 14 hours in the presence of 5.6, 11, and 20 mM glucose. Results show increasing 
insulin mRNA synthesis with increasing glucose concentration. (B) Expressed rela-
tive to the density of the β-actin gene PCR product, insulin expression is greater than 
4-fold higher at 20 mM compared with 5.6 mM glucose. There is an expected reduc-
tion (~2-fold) in glucagon expression at 20 mM compared with 5.6 mM glucose due to 
the known suppression of glucagon secretion by high glucose and insulin concentra-
tions (55–57). (C) Coculture of islet cells at different glucose concentrations with 1E6 
PPI15–24–specific T cell clone results in a significant increase (1-way ANOVA, P < 0.01) 
in TNF-α production by the clone, with a significant linear trend as glucose concentra-
tion increases (P < 0.005), indicating an increase in epitope presentation at higher 
glucose concentration. (D) A similar analysis of islets precultured at different glucose 
concentrations and prepulsed with PPI15–24 peptide shows that high glucose alone has 
no effect on T cell clone activation. Symbols indicate different effector/target ratios of 
3:1 (circles), 6:1 (diamonds), 12:1 (inverted triangles), and 25:1 (triangles).
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partial sequence information under collision-induced dissociation (CID) 
using atmospheric gas. The MS/MS spectrum for each unique mass was 
submitted to a Mascot server (35), querying either the NCBI nr (nonredun-
dant) (36) or a local database to identify the precursor sequence.
Subjects. Fresh heparinized and clotted blood samples were obtained from 
56 HLA-A*0201 patients of mixed European descent with type 1 diabetes 
(mean ± SD age, 29 years ± 6.5; median duration of disease 10 weeks, range 
3–14 weeks) with acute onset of symptoms requiring insulin from the 
time of diagnosis and 36 HLA-A*0201 nondiabetic control subjects, also of 
mixed European descent, without history of first-degree relatives with type 
1 diabetes and matched for age (mean ± SD age, 31 ± 5.7 years). All samples 
were screened initially for HLA-A2 by flow cytometry (using the BB7.2 
mAb clone; BD Biosciences — Pharmingen), and HLA-A1*0201 positivity 
was confirmed by PCR sequence-specific primer (PCR-SSP) genotyping. 
Fresh PBMCs were isolated on density gradients (Lymphoprep; Nycomed) 
and washed in RPMI-1640 (Invitrogen) twice before use. These studies were 
carried out with the approval of King’s College Hospital Research Ethics 
Committee, and informed consent was obtained from all participants.
ELISPOT for the detection of CD8+ T cell responses. Fresh PBMCs were pre-
cultured in single wells of 48-well plates at a density of 1 × 106 in 0.5 ml 
TC medium (RPMI-1640, antibiotics from Invitrogen, and 10% human 
AB serum from PAA) containing test peptide to a final concentration of 
10 μM and incubated at 37°C, 5% CO2, tilted by 5°. Peptides were synthe-
sized by standard Fmoc chemistry (Interactiva Biotechnologie GmbH) to 
at least 90% purity as confirmed using RP-HPLC and MS. Control wells 
contained TC medium with an equivalent concentration of DMSO or CEF 
(viral peptide mix, at a final concentration equivalent to 10 μM; Mabtech). 
After 24 hours incubation, nonadherent cells were resuspended using pre-
Figure 8
High ambient glucose increases the efficiency of human β cell killing. (A) Specific lysis of human islet cells after 14 hours preculture at different 
glucose concentrations (5.6 mM, 11 mM, and 20 mM; filled squares, filled circles, and open squares, respectively). Higher glucose results in 
significantly enhanced CTL killing by 1E6 (1-way ANOVA, P < 0.005; significant linear trend, P < 0.005). Representative agarose gel of RT-PCR 
amplification using insulin- and glucagon-specific primers of total RNA from human islet cells after 14 hours at different glucose concentrations 
(B) and band density in the same gel (C). Islet cells at 5.6, 11, and 20 mM glucose exposed to killing by 1E6 clone cells show increasing loss 
of insulin mRNA, declining from approximately 50,000 to approximately 0 counts. Glucagon expression is identical to that at 20 mM glucose in 
the absence of 1E6 clone cells (see Figure 7A). (D) In contrast, human islet cells pulsed with PPI15–24 show no β cell specificity of killing and no 
additive killing at higher glucose concentrations (symbols as above). (E) Agarose gel of RT-PCR using insulin- and glucagon-specific primers 
after human islet cells were cultured for 14 hours at 20 mM glucose, either with PPI15–24 peptide and exposed to killing by 1E6 (lane 1) or cultured 
alone (lane 2) and (F) graphical representation of band density. The results show loss of both insulin and glucagon expression, demonstrating 
a lack of β cell–specific killing of islets prepulsed with PPI15–24. Cytotoxicity assays were performed in triplicate; symbols represent means, and 
error bars represent SEMs.
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warmed TC medium (2% AB serum), washed, and brought to a concen-
tration of 106/300 μl, and 100 μl was dispensed in triplicate into wells of 
96-well ELISA plates (Nunc MaxiSorp) preblocked with 1% BSA in PBS and 
precoated with monoclonal anti–IFN-γ (U-CyTech Biosciences). In some 
assays, harvested cells were depleted of CD8+ T cells using immunomag-
netic beads (Miltenyi Biotec). After cytokine capture at 37°C, 5% CO2 for 
15 hours, cells were lysed in ice-cold double-distilled water, plates washed 
in PBS/Tween-20 (0.05%), and spots developed according to the manu-
facturer’s instructions. Plates were dried and spots of greater than 60 μm 
counted in a BioReader 3000 (Bio-Sys). Triplicate values were pooled to 
provide total spots per 106 PBMCs, and values obtained in test wells were 
compared with the background (DMSO) wells to derive a stimulation index 
(SI). In preliminary studies using insulin/proinsulin peptides known to 
elicit responses in patients with type 1 diabetes (14, 15, 24, 37), the optimal 
operating conditions for the assay were established using a receiver-opera-
tor characteristic (ROC) curve as described previously (9), and samples were 
considered positive when the SI was at least 2. In a subset of patients and 
control subjects (n = 15 per group), additional non-
islet peptides were included as controls for nonspe-
cific reactivity: an immunodominant epitope of the E2 
component of pyruvate dehydrogenase complexes, the 
major mitochondrial antigen in primary biliary cirrho-
sis residues 159–167: KLSEGDLLA (38); an epitope of 
the circumsporozoite protein of Plasmodium falciparum 
variant NF54 residues 334–342: YLNKIQNSL (39); 
and an HLA-A2–derived peptide eluted from HLA-A2 
(B.O. Roep et al., unpublished observations) residues 
140–149: YAYDGKDYIA. For the remaining subjects 
(n = 41 patients and n = 21 controls), the human islet 
amyloid polypeptide precursor protein 5–13 (IAPP5–13) 
(KLQVFLIVL) (40, 41) was used as a control for non-
specific reactivity to SPs. Positive ELISPOT responses 
to IAPP5–13 were present in 4 of 41 patients (9.7%) and 4 
of 21 control subjects (19%; P = NS).
Generation of CD8+ T cell clones. Monocyte-derived DCs 
were obtained as described previously (42) and used to 
generate mature DCs. DCs were pulsed with 10 μg/ml 
PPI15–24 peptide for 1 hour at 37°C in IMDM/AB 
medium (Invitrogen). After extensive washing, mono-
cyte-derived DCs and autologous CD8+ lymphocytes 
(purified from PBMCs using the CD8 Isolation Kit II; 
Miltenyi Biotec) were cultured at a 1:5 ratio in 24-well 
culture plates. Initial culture medium IMDM/AB was 
supplemented with IL-7 (10 ng/ml; PeproTech). After 2 days, 5% Cellkine 
(ZeptoMetrix Corp.) and IL-15 (0.1 ng/ml; PeproTech) were added. After 
7 days of culture, CTLs were restimulated with mature autologous DCs 
(pulsed with 10 μg/ml PPI15–24) at a 1:5 ratio. On day 22, CD3+CD8+ T 
cells staining with PPI15–24–Tmr and negative for 7-aminoactinomycin-D 
(live/dead discriminator) were flow sorted and seeded at 1 cell/well in 
96-well plates, each well containing 1 × 105 irradiated allogeneic PBMCs, in 
X-Vivo 15 (BioWhittaker) and 5% Cellkine, IL-7 (10 ng/ml), IL-15 (0.1 ng/ml), 
and PHA-M (5 μg/ml; Sigma-Aldrich). Growing CD8+ T cell clones were 
isolated and restimulated every 14 days as described above. Phenotypic 
analysis of clones was carried out as previously described (43) using the 
following mAbs for surface and intracellular staining (43): anti-CD3, anti-
CD4, anti-CD56, anti-CD16, anti-CD8, anti–TCR-αβ, anti-NKG2D, anti-
CD28, anti-CD45RA, anti-CD45RO, anti-CXCR3, anti–TNF-α, anti–IFN-γ, 
anti–granzyme B, anti-perforin, and anti-TRAIL (all from BD and BD Bio-
sciences — Pharmingen); anti-CCR7 and anti-CCR4 (both from R&D Sys-
tems); anti-CD62L and anti-CD44 (both from Serotec Ltd).
Figure 9
Enhanced islet killing at high glucose concentration is related to trans-
lation of insulin mRNA rather than insulin secretion. Analysis of islet 
cell killing in relation to insulin secretion and insulin mRNA expression. 
Human A2+ islets were cultured for the specified time periods in the 
presence of 20 mM glucose, and at the end of that time, islet cells 
were removed into a cytotoxicity assay with clone 3F2. White bars 
show insulin secretion over the periods 0–1 hours, 1–8 hours, and 
8–16 hours. Gray bars show insulin mRNA expression above baseline 
(designated 1,000 AU, measured as IOD) in islets harvested at the 
specified time points. The line graph with open circles shows killing of 
islets harvested at the specified time points. The results show that β 
cells exposed to high glucose degranulate rapidly but that this is not 
related to enhanced killing by PPI15–24–specific CTLs. The relationship 
between insulin mRNA levels and killing suggests that PPI15–24 genera-
tion is related to levels of PPI transcription and translation rather than 
to insulin secretion.
Figure 10
PPI SP epitope PPI15–24 is cross-presented by DCs from intact PPI and PPI-expressing 
cells. (A) DCs pulsed with soluble PPI and then matured induce TNF-α production by 
1E6 PPI15–24–specific T cells. Cytokine production in the presence of a control protein (the 
fusion partner of recombinant human PPI) and PPI15–24 peptide are shown for compari-
son. (B) DCs pulsed with freeze-thawed K562 cells expressing PPI (K562-PPI) and then 
matured induce TNF-α production by 1E6 clone cells. Cytokine production in the presence 
of control cells (nontransfected K562) and PPI15–24 peptide are shown for comparison. 
Bars represent means from triplicate experiments, error bars SEMs; data are representa-
tive of 3 independent experiments.
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Functional analysis of clones was carried out after stimulation with 
peptide-pulsed DCs, PBMCs, and variously transfected K562 cell lines, 
using [3H]thymidine incorporation, TNF-α secretion (measured by ELISA 
from ImmunoTools), or intracellular TNF-α and IFN-γ expression (mea-
sured by flow cytometry). As a control, we used the same approach to 
clone CD8+ T cells recognizing the immunodominant HLA-A2–restricted 
CMV pp65 peptide NLVPMVATV.
Human islet isolation, culture, and cytotoxicity assays. Human islet isolations 
were performed using a method described previously (44). Pancreata were 
retrieved with the consent of donors’ relatives and permission of the Ethical 
Review Committee of King’s College Hospital. Islet-enriched cell fractions 
were cultured in CMRL1066 containing 5.6 mM glucose, supplemented with 
10% FBS and penicillin (100 U/ml), streptomycin (100 μg/ml), and l-gluta-
mine (2 mmol/l) (Invitrogen) for 2 weeks, with medium changed every 2 days. 
Cells were allowed to become monolayer cultures and before cytotoxicity 
assays were cultured in the presence of cytokines (500 IU/ml IFN-γ; 
50 IU/ml IL-1β; 2,500 IU/ml TNF-α [Strathmann Biotec] and 1,000 IU/ml 
IFN-α [Roche Laboratories]) for 16–24 hours to upregulate HLA class I 
expression (cytokines and concentrations established in preliminary stud-
ies and selected for optimal upregulation).
Cytotoxicity was analyzed by a nonradioactive europium TDA (EuTDA) 
cytotoxicity assay using DELFIA Technology (PerkinElmer) according 
to the manufacturer’s instructions (45). Briefly, either human islet cells 
(1 × 106) or K562-PPI-A2, K562-A2, or K562-PPI-A2-UL49.5 cell lines were 
incubated for 20 minutes at 37°C in 1 ml of RPMI/10% FBS with 3 μl of 
fluorescence-enhancing ligand. After extensive washing with PBS (5 times), 
50 μl of labeled islet cells (5 × 103) were seeded in triplicate into V-shaped 
96-well plates followed by 50 μl of effector cells (CD8+ T cell clone) at vary-
ing ratios in X-Vivo 15/5% AB serum/IL-7 (10 ng/ml), IL-15 (0.1 ng/ml), and 
2.5% Cellkine. The cultures were incubated for 4 hours at 37°C, and 20 μl of 
the supernatant transferred to a clear, flat-bottom microtitration plate, fol-
lowed by addition of 200 μl/well of enhancement solution. After 15 minutes 
at room temperature with shaking, the europium signal was measured using 
a VICTOR3 Time-Resolved Fluorescence Reader (PerkinElmer). To deter-
mine maximum lysis, islet cells alone (5 × 103 in 100 μl) were treated with 
20 μl lysis buffer. Spontaneous release was measured from wells containing 
only labeled islet cells in 100-μl volume. Specific cytotoxicity was calculated 
using the following formula: % specific release = (experimental – spontane-
ous release) × 100/(maximum – spontaneous release). In some experiments, 
islet cell monolayers were cultured for 14 hours before cytotoxicity assays in 
the presence of 11 mM or 20 mM glucose.
Detection of insulin and glucagon mRNA. Semiquantitative RT-PCR was per-
formed using total RNA isolated using an RNA Miniprep Kit (Promega) 
and quantified using a spectrometer (GeneQuant II; Pharmacia Biotech) at 
260-nm wavelength as described previously (44, 46, 47). Briefly, 100 ng of 
total RNA was converted into first-strand cDNA using RT (Invitrogen) in a 
volume of 20 μl. The hot-start (QIAGEN) RT-PCR was used with the follow-
ing parameters: 95°C for 15 minutes for 1 cycle; then various amplification 
cycles for individual genes. Human β-actin gene was amplified in parallel as 
an internal control. The PCR primers used were: human insulin–forward 
(5′-CATCAAGCACATTGTCC-3′) and –reverse (5′-CTGGTTCAAGGGCTT-
TATTC-3′); human glucagon–forward (5′-GCATTTACTTTGTGGCT-
GGGTC3’) and –reverse (5′-AGTGATTTTGGTCTGAATC-3′); human 
β-actin–forward (5′-CCCAGATCATGTTTGAGACC-3′) and –reverse 
(5′-CCAACAGGAGTACTTGCGCTCAG-3′). DNA relative quantity was ana-
lyzed using a gel program (version 3.0 computer analyzer of Media Cyber-
netics) and expressed relative to the density of the β-actin gene PCR prod-
uct. For analyzing small quantities of RNA following cytotoxicity assays, 
RNA derived from 106 HEK 293 cells was added to each assay sample before 
cDNA synthesis (HEK 293 cells do not express insulin or glucagon).
Analysis of processing of PPI SP epitopes. In vitro proteasome-mediated diges-
tions were carried out as described previously (14). In brief, 20S proteasomes 
were purified from an Epstein-Barr virus (immunoproteasome) and a HeLa 
cell line (constitutive proteasome) as described (48). Low-molecular-mass 
polypeptide 2 (LMP2) and LMP7 contents were confirmed by 2D immu-
noblotting. To assess kinetics, digestions were performed during different 
incubation periods. The PPI1–30 synthetic peptide (20 μg) was incubated 
with 1 μg of purified proteasome at 37°C for 2 and 20 hours in 300 μl of 
proteasome digestion buffer (49). TFA (1%; 30 μl) was added to halt the 
digestion, and samples were stored at –20°C until MS analysis.
Cross-presentation of PPI SP epitopes. To examine cross-presentation of PPI 
SP epitopes by DCs, FastDC were generated from a HLA-A2+ donor based 
on a method previously described (50) and pulsed with soluble antigen 
(PPI generated in E. coli as described [ref. 9] or purification tag alone as 
control, both at 20 μg/ml) or heat-killed PPI-expressing cells (K562-PPI 
and K562 as control; 1:1 equivalent ratio with DCs) for 6 hours prior to 
addition of maturation factors (1,000 IU/ml TNF-α and 10 ng/ml IL-1β, 
both from Strathmann Biotec; and 1 μM PGE2 from Sigma-Aldrich). After 
overnight culture, DCs were harvested, washed twice, and cultured with 
PPI15–24–specific T cell clone at a 5:1 ratio (T/DC) for 24 hours, after which 
supernatants were removed and TNF-α measured by ELISA.
Statistics. Differences in frequencies of responses in study groups were 
compared using Fisher’s exact test. ROC plots were generated as described 
previously (9). The effects of glucose concentration were analyzed by 1-way 
ANOVA with repeated-measures test and test for linear trend. Compari-
sons were carried out using GraphPad Prism software and considered sig-
nificant when P was less than 0.05.
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